WONDERFUL
WONDERFUL Registry: A Multicenter Prospective Observational Study of Local Complications of Acute Pancreatitis and Postoperative Pancreatic Fistula
Sponsor study identifier
Secondary identifiers
REGISTRY · UMIN Clinical Trials Registry
observational
5,000
1 country
12
Study Start
September 14, 2023
Actual (reported)Primary Completion
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
This multicenter prospective observational registry will evaluate the clinical characteristics and treatment outcomes of adults with local complications of acute pancreatitis or postoperative pancreatic fistula. Data generated during routine clinical care, including patient characteristics, imaging findings, treatments, adverse events, recurrence, and clinical outcomes, will be collected. Treatment is determined by the treating physicians and is not assigned by the study protocol.
Registry-reported information. Elapsed time and enrollment totals alone do not measure study progress or recruitment pace.
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Click on a node to explore related trials.
Some registry-reported names shown below are not yet linked in this graph.
Dates and qualifiers reported by the registry. Estimated dates do not confirm that a milestone has occurred.
September 14, 2023
Actual (reported)September 16, 2026
Actual (reported)October 7, 2026
Actual (reported)July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Proportion of Participants Achieving Clinical Success Within 180 Days
Clinical success is defined as resolution of the symptoms and clinical signs that required treatment, together with resolution or marked reduction of the target fluid collection on follow-up imaging. For infection-related cases, improvement in at least two of body temperature, white blood cell count, and C-reactive protein is required.
Within 180 days after enrollment
Proportion of Participants With Technical Success of the Initial Intervention
On the day of the initial intervention (1 day per participant)
Procedure-Related Adverse Events
Within 180 days after enrollment
Adults receiving routine clinical care for local complications of acute pancreatitis or postoperative pancreatic fistula. Management may include conservative care, endoscopic or percutaneous intervention, or surgery. No intervention is assigned by the study.
Participants receive routine clinical management selected by their treating clinicians. Management may include conservative treatment, endoscopic or percutaneous drainage, necrosectomy, stent placement, or surgery when clinically indicated. No diagnostic or therapeutic procedure is assigned by the study protocol.
Registry-reported names are shown in full. Names without a link have not yet been matched to a Syfrah profile.
Adults receiving routine inpatient or outpatient care at participating institutions for local complications of acute pancreatitis or postoperative pancreatic fistula.
Department of Gastroenterology, Shiga University of Medical Science
Ōtsu, Shiga, 520-2192, Japan
Department of Gastroenterology, Graduate School of Medicine, Juntendo University
Bunkyō-Ku, Tokyo, Japan
Banks PA, Bollen TL, Dervenis C, Gooszen HG, Johnson CD, Sarr MG, Tsiotos GG, Vege SS; Acute Pancreatitis Classification Working Group. Classification of acute pancreatitis--2012: revision of the Atlanta classification and definitions by international consensus. Gut. 2013 Jan;62(1):102-11. doi: 10.1136/gutjnl-2012-302779. Epub 2012 Oct 25.
Tomotaka Saito, MD, PhD
Graduate School of Medicine, The University of Tokyo
First Submitted
September 16, 2026
First Posted
October 7, 2026
Study Start
September 14, 2023
Actual (reported)Primary Completion
July 31, 2028
EstimatedNeutrophil/Lymphocyte Ratio in Acute Pancreatitis
Need for Additional Intervention
Within 180 days after enrollment
Recurrence of the Target Fluid Collection
Within 180 days after enrollment
All-Cause Mortality
Within 180 days after enrollment
Contact the study team to confirm eligibility.
The University of Tokyo Hospital
Tokyo, Tokyo, 113-8655, Japan
Department of Gastroenterology, Tokyo Women's Medical University
Tokyo, Tokyo, 162-8666, Japan
Department of Gastroenterology, Gifu Municipal Hospital
Gifu, Japan
Department of Gastroenterology, Gifu Prefectural General Medical Center
Gifu, Japan
First Department of Internal Medicine, Gifu University Hospital
Gifu, Japan
Division of Hepatobiliary and Pancreatic Diseases, Department of Gastroenterology, Hyogo Medical University
Hyōgo, Japan
Department of Gastroenterology and Hepatology, Saitama Medical Center, Saitama Medical University
Kawagoe, Japan
Division of Gastroenterology, Department of Internal Medicine, Kobe University Graduate School of Medicine
Kobe, Japan
Department of Gastroenterology and Hepatology, Kindai University Faculty of Medicine
Ōsaka-sayama, Japan
Third Department of Internal Medicine, University of Toyama
Toyama, Japan
Planned date reported by the registry; this milestone is not confirmed as achieved.
Study Completion
July 31, 2028
EstimatedPlanned date reported by the registry; this milestone is not confirmed as achieved.
Last Updated
October 7, 2026
Record last verified: 2026-10
Download the complete ClinicalTrials.gov record imported by Syfrah, including fields not shown in this page. The registry may contain a newer revision.
Source: ClinicalTrials.gov.
JSON downloads include source attribution and retrieval details alongside the unchanged original record or the separately normalized values.
Source retrieved: